Let's evaluate Trump's obesity deal. For background, today Trump announced that his administration had negotiated the price of GLP-1 receptor agonist (GLP-1RA) anti-obesity drugs down considerably. If you're unfamiliar, these are drugs like Ozempic and Zepbound. These drugs work amazingly. In trials, virtually all side effects are mild and transient, and as a result, the discontinuation rate is usually on the order of 6%, and it can be lowered further if people ramp up their doses more slowly to avoid side effects. In the real world, continuous use of these drugs is around 80% over several years, and most people quit because of cost, which is what Trump aimed to deal with here today. To get an idea of what these drugs can do for America, consider what would happen if we put every obese (BMI > 30) person on them. If they all stayed on at reasonable doses, then within one year, the obesity rate would more than halve with Ozempic/Wegovy (Semaglutide), would decline by three-quarters with Zepbound/Mounjaro (Tirzepatide). It would decline by over 80% with Eli Lilly's next-generation GLP-1RA, Retatrutide (no brand name yet). If this happens, it means eliminating most chronic disease in America, and this is just with one year of usage. If we abstract and talk about age-unrelated chronic disease, then this eliminates the vast majority of it in one year. This could be a huge health win, so it is extremely good that Trump is making it happen. So, briefly, today, Trump committed to tackling the obesity epidemic. This is among the only policies in American history that actually, materially helps with that. Other examples include banning trans fats, subsidizing polyunsaturated fats, etc., but practically nothing else has had any impact on the obesity rate, nor will anything else, because people things like 'telling people to exercise more and eat better' do not actually motivate people to change their habits at scale. What did he actually end up doing? Let's go by market segment. --- For cash pay or self-pay customers: Using the new TrumpRx web portal (available soon), you can - Obtain injectable GLP-1RAs (Semaglutide/Tirzepatide) starting at an average price of approximately $350/month, and this average price will eventually drop to $245/month over the next two years. -- Eli Lilly indicated that this means that the lowest dose for Zepbound (their prescription weight loss Tirzepatide product) will be $299/month, with higher doses all available at $449/month. - Initial doses of oral Semaglutide will start at $149/month when they come to market -- We do not have other pricing information for oral Semaglutide - When Orforglipron is brought to the market, starting doses will be capped at $150/month - Oral GLP-1 or equivalent starting doses are capped at $399/month - All future GLP-1 products will be priced at the lowest price paid by wealth comparator countries, but it is unclear if this applies to TrumpRx purchasing immediately on release So, what does this mean for out-of-pocket/self-pay/cash pay purchasers? Not much. Firstly, the top self-pay price for Semaglutide was already $499/month, and that was the same top price for Tirzepatide, which has now dropped to $449. The additional cuts barely move the needle, so the number of self-payers who will start using these drugs as a result of the cuts is minimal. Secondly, these prices are still vastly inferior to gray market prices or the generic import prices that could be achieved if the administration changed a small number of rules having to do with the Section 804 Importation Program. These self-pay improvements will likely only get a few hundred thousand additional people using these drugs, and they will not use them on a continuous enough basis, or at high enough doses to achieve meaningful population-level effects until two years from now, whereafter they still won't have a quantitatively large effect. Sorry, but consumers want this stuff at <$100/month, not $449. Self-pay customers are still better off using compounders, which is where the self-pay competition is. The compounder going rate for Tirzepatide and Semaglutide is under $200, so this plan fails to expand access except through getting the word out and providing compounding skeptics and gray market + compounding skeptics with a small price haircut. Self-Pay Verdict: 1/5 stars. --- For Medicare and Medicaid beneficiaries: Firstly, states need to opt in to get Medicaid discounts. Assuming they do that: - The government purchase price drops from $245 from current net prices around $700 for Semaglutide and $520 for Tirzepatide - Eligible patients only have to pay $50/month - Medicare will only be covering GLP-1RAs for obesity/overweight with comorbidities, which include reaching certain BMI thresholds, cardiovascular disease, and kidney disease -- That means roughly 10% of Medicare enrollees may become eligible - Medicaid can be more tailored at the state level, which means potentially wider eligibility -- That means that >40% of Medicaid enrollees can become eligible based on obesity prevalence So, what does this mean for Medicare and Medicaid beneficiaries? It depends. Firstly, the restrictions for Medicare are too high. You would get better results just making this an obesity thing. By restricting this to after comorbidities show up or obesity becomes severe enough, you are allowing the accumulative damage from obesity and its attendant lifestyle to increase future costs. So, for example, waiting for cardiovascular risk means you have to pay for that when it's realized, instead of just getting ahead of it by tackling obesity alone. Secondly, people will want to get off and come on these drugs at a lower threshold than obesity. If you cut people off at a BMI of 29.9, you will leave them overweight, unhappy, and probably not where they need to be in terms of fat to lean mass ratio, central adiposity, and other important measures. You are basically begging for people to yo-yo on these drugs around an uncomfortable, medically inadvisable threshold. Third, let's be real: state Medicaid plans will not all get on board with this at current prices, and they will probably copy the Medicare eligibility criteria because they're available. The administration needs to advise them to provide expansive access based on *obesity or overweight* right now. Importantly, it is more economically beneficial to do this with Medicaid because of the generally younger people in the plans (generally: about 12m people are dual-enrollees this year). Under optimal conditions, this will expand coverage to about 7 million people in Medicare and 29-30 million adults in Medicaid, and potentially another 3-4 million adolescents, for a total increase of 39-41 million, with many millions more Medicare enrollees becoming eligible over the coming years, and the share of them who are eligible rising due to aging. This means expanded coverage in a temporary sense for basically the whole of the 70m, potentially. Medicare/Medicaid Verdict: 2.5/5 stars with the potential to go to 4/5 if you sweeten the deal for states (more opt-ins) and adjust the thresholds for coverage --- What was exchanged for this? Trump gave Eli Lilly and Novo Nordisk three years free from pharmaceutical import tariffs and he provided gave Eli Lilly expedited review for Orforglipron, their oral GLP-1 drug. He also gave Novo Nordisk expedited review to add another indication for Semaglutide. These are things that *are good for the CMS, insurers, etc.*, so they are actually a way to make the country richer in their own right. The nature of this deal is like Novo Nordisk and Eli Lilly going up to Trump and saying 'If you let us clean your house and cook you a nice meal, we'll also give you cheap drugs.' I rate the terms for these companies very highly! 5/5 on that basis, but 2/5 for not including anything to do with increasing competition, generic access, etc., which are the real drivers of price reductions. Additionally, a few companies including Eli Lilly and Novo Nordisk have offered to lower other drug costs. For Novo Nordisk, that means cutting NovoLog costs by more than half to $35/month via TrumpRx and lying to the government about cutting Tresiba to $35/month, when that's already the coupon price. That increases eligibility somewhat, but not meaningfully. Novo pulled one over on Trump with this move. For Eli Lilly, that means cutting Emgality to... an amount above the Part D price, about 9x the coupon price... And... less than the current net prices, but insurers can't pay this rate! OK, another dupe, basically. They also agreed to cut Trulicity to... about 12-13x the price 92% of people pay for it already and close to the net price. Duped. These deal sweeteners only help a very small number of people. They are basically gimmes that Novo and Lilly could throw out without doing anything to their bottom lines, and the portrayal of them as anything other than that is farcical. If whoever negotiated this was convinced that these added any value, then they should probably be replaced because this adds almost nothing. Sorry! 1/5 on the deal sweeteners. --- How would I rate Trump's deal? 2.75/5 stars, a good start, but it needs work. Upside: - This expands coverage - This saves the government money - This reduces the leverage these companies have for future negotiations - It is now decisively worth it for the government to pay for GLP-1RAs at these prices. They pass any reasonable cost-benefit test for America's public health options. Downside: - Coverage barely expands in terms of population percentage covered for non-CMS options - This doesn't save as much money as if alternative options were achieved - The thresholds for coverage that have been revealed are quite bad - This fails to achieve large population-level health effects that will help to make these drugs self-financing, because it is focused on the old, who are net takers. They will live longer thanks to these drugs, which is great, but they will eat more from the public purse, cutting into the financial upside relative to wider distribution. Suggestions: - Keep going. This deal is not enough by any means. - Negotiate the patent. This can likely only be accomplished alongside Congress - Use the FTC to crush evergreening and similar practices and go after these companies until they offer a better deal, a generic, etc. - Pursue the SIP option because it is quite literally free, good for relations with Canada if we want to do it right, and it is likely to bring much lower prices than what the administration (but not Congress!) can actually negotiate (https://www.cremieux.xyz/p/a-modest-proposal-to-turn-canada) - Give priority review to competitors - Increase the personal use importation allowance - Deregulate 503A/B, cut the bulk list and difficult to compound entirely, etc. - Stop the FDA from interfering with compounders, put price pressure on Novo and Lilly so they come back with a better deal (they CAN do better) - Force lower caps on higher doses. It is basically a scam to give people a competitive introductory dose and then to force them off due to price when they titrate up. Utility is pitiful until this is achieved - Refer patients to compounders in TrumpRx. You can do this, it will just make Novo and Lilly very upset - Lower the suggested Medicare thresholds. They're not well thought out right now - Lean on the Part D $2,000 out-of-pocket cap and smoothing by pushing plans to auto-enroll eligible members in smoothing so the cap bites for GLP-1 users - Pursue expanding indications for Tirzepatide products. We already know that Semaglutide does nothing special beyond Tirzepatide, so expand the CV indication already. You know you're going to eventually, just use the newly-allowed mechanistic arguments that were being applied for approvals for an indication increase. This makes everyone happy! -- On that note, issue a model prior-auth that's minimal and uniform and leans on the cardiovascular risk indication for Wegovy for non-obesity cases. Apply it to overweight if you're cautious or frugal. - Fast-track state opt-ins (obvious, just needed to say it) - Aggregate Medicare, Medicaid, VA/DoD/IHS buying to the extent permitted by law and negotiate dose-agnostic ceilings so higher doses don't erase savings, like they appear poised to do. Pair this with outcomes clauses to claw back if discontinuation rates are high. Approve new titration schedules to help with that. - Long shot: Just approve Mazdutide and other GLP-1RAs approved in other ICH countries. Won't do much, but will do something, and is very easy. - Shine a light on net prices and dose-step pricing, because publicity alone narrows dosage-related pricing gaps. CMS underutilizes its messaging abilities to do good - Use the upcoming Medicare negotiations as a threat to get prices down more, negotiate the patent, etc. - If Trump actually breaks the filibuster, just fully expand Section 804, buy out the patent from Novo Nordisk, and push generics immediately, etc. This alone probably brings the price down to $20/mo nationally and ends obesity. - Lots more. AMA. --- Bottom Line: The current deal doesn't do enough, but it could be readily improved. Get on it already! --- Also, I want the admin to clean up the numerous errors on the announcement page. 75% of pharmaceutical profits are not from American *taxpayers*, for example. --- Sources: https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/ https://www.cremieux.xyz/p/the-worst-argument-against-ozempic https://www.cremieux.xyz/p/could-universal-glp-1-drugs-end-the https://www.cremieux.xyz/p/a-modest-proposal-to-turn-canada --- GLP-1RAs help basically everyone: https://www.cremieux.xyz/p/there-are-no-more-excuses-to-be-fat You can get GLP-1RAs for very cheap via the gray market: https://www.cremieux.xyz/p/how-to-get-cheap-ozempic
- First collected
- 2026-11-04 14:46 UTC
- Last seen on X
- 2026-11-04 14:46 UTC
- Added to this archive
- 2026-11-11
- Fingerprint
ef4706fad565e8f7d5c6ee2805f432a909fd2760337f1a5c440c5f44951c5d60- Permanent address
- /#post/1986609174847840276